Some of this article is a bit difficult to follow, and money is probably a major motivator behind ProNeuron’s accusations that Teva has sabotaged clinical trials. But ProNeuron claims it has evidence that lower doses of COP-1, the active ingredient in Copaxone, may be effective for some neurodegenerative diseases, and it suggests that this might have implications for MS users of Copaxone. ProNeuron claims that Teva has not pursued this because they want to reap the benefits of having patients inject Copaxone daily.

Between currents studies of double dose Copaxone and this article, it sounds like the story about the most effective dosage for Copaxone is far from over. It would be worth tracking this law suite to see if the claims are indeed true.